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taken at the time of combined heart-lung transplant. ATI and AT2 receptor
binding were determined by competitive displacement with the ATI receptor
antagonist Iosarfan. Comparison was made to nonfailing, nordransplantsd
@nor hearts.
Group ACEBIIW TotslATR AT, AT2
PPH LV (n = 8) 712 &S6* 9.93* 1.44 6.41 + 1.23 3,52 + 0,55
PPHRV~n=6) 6S7+ 136* 5.37k l.O@ 2.37* 0.5#.* 3.00+ 0.76
NFLVh = 2S-28) 341*2S 7.66+ 0.53 5.27+0.50 2.39+0.30
NFRV\n .S-11)” 344+53 10.2* 1.20 7.46* 1.00 2.79 + 0.41
Readte shownare mean k SE fmolrmgproteinfor all catsgoriso.NF= nonfallingdonor
heart;LV= Isftventriole;RV= rightventricle.*p <0.05 va.NFLV:~p<0.05 vs.PPHLV;
*P< 0.05vs,NFFIV(ANOVA).
Conclusions: 1) ACE binding sites were increased in both RV and LV of
PPH hearts comparsd to NF RVand NF LV;2) ATI receptorswere selectively
decreased in PPH RV compared to PPH LV and NF RV.These data suggest
that systemic mechanisms regulate ACE whereas local factors related to
pressure overload of the RV modulate ATI receptor deneify in PPH.
a976154 TheEffectsof AntihypertenslveDrugsonSusceptibilityto VentricularArrhythmia,
Regraaaionof LeftVentricularHypertrophy,of
CerdiacFibroeieandPostinfarctionMortaiity
T. Nguyen, J.L. Rouleau. Monlreal Heart Institute, Montreal, Quebec,
Canatia
Hypertension and left ventricular hypettrophy (LVH) are known to increase
the riak of ventricular arrhythmias (VA) and the risk of dying during an
aoute myocardial infarction (Ml). In this study, We assessed the effects of
3 antihypettensive drugs on regression of LVH and cardiac fibrosis (CF),
inducibility of VA and survival post Ml in 86 male spontaneous hypertensive
rats with evidence of LVH. Twenty-five served as controls (Ctl); 20 received
Captopril (Cap) which normalized systolic biood pressure (BP), reduced LVH
and CF, 20 received Propranolol (Pro) which reduced heart rate (HR) but
did not reduce BP or LVH and 21 received Hydralszine (Hyd) which lowered
BP, reduced slightly LVH and CF. After 12 weeks of therapy, medications
were stopped for 72 hra prior to Programmed Electrical Stimulation (PES).
Immediately after PES, an acute Ml was produced by ligation of the LAD at
ite origin and survival at 3 hrs was evaluated.
Gr (n) BP [mmHg) HR (bpm) LV/TB VA CF (%) CF Mortality
.,
week 12 “ week ~2” (mg/g) (o/o) vol. dens. Total. (%)
Ctl (25) 193 i 12 501 &28 2.6+ 0.1 35 3.2 + 1.1 9.0 71
Pro 120) 165 &12 337* 22* 2.6 k 0.3 11+ 2.3+ 0.6” 6.4* 70
cap’f2s) 83* 14* 496+45 2.2+0.2” 5* 2.0 * 0.7” 4,4’ 40*
Hyd (21) 126+ 13* 531 + 16* 2.6+ 0.2” 25 2.9 + 0.9” 7.6 67
LVrTB=lettventricular/tOtalbdY weight;CFtOtat=CFvOL derwityx LVrTB(OAgrmg).*p
<0.05, +p <0.1 vs controlby ANOVA
According to the results, Cap significantly decreased inducibility of VA,
whereas Hyd tendad to reduce CF but did not significantly reduce LVH
suggesting that marked rather than mild regression of LVH ia neceasaty
in order to improve survival in this model. Thus, the morphologic changes
that accompany the hypotension effects of Cap result in a decrease ‘in
susceptibility to arrhythmias and peri-infarcf mortality.
at Columbia (CPMC) (7/93-10/95), and included serum Na+, reating HR,
LVEF,mean BP,peak V02, ischemic etiology and QRS z 120 maec. SD and
nonsudden cardiac death (NSCD) groups were compared by Wilooxon and
t-tests. Kaplan-Meier freedom from SD and NSCD were determined, with
URGTXP considered a NSCD. Predictions of any event, SD and NSCD at 1
year were assessed by determining the areas under the ROC cuwe (AUC).
Freedom from SD @ l-year was 92 + 2% (HUP), 93 + 2% (CPMC).
Freedom from NSCD @ 1 year was 84 & 2% (HLJP),75 + 3% (CPMC).
Most clinicel characteristics were similar in SD and NSCD patients. There
were no differences between groupe for NYHA class, cardiac index or 6 of 7
model variables. Peak V02 (ml/kg/min) tended to be higher for patients with
SD (14.6 + 5.2 VS. 12.5 + 3.9, p = 0.04 [HUP]; 15.9 + 4.8 VS.13.9 + 3.4,
p = 0.06 [CPMC]). Overall discrimination for event-free suwival (AUC = 0.81
[HUP], 0.79 [CPMC]) and NSCD (0.82+ 0.04 [HUP], 0.78 + 0.04 [CPMC])
was good. AUC for SD was slightly worse (0,75 + 0.05 [HUP], 0.66 & 0.08
[CPMC]).
In conclusion, the incidence of sudden death was quite low in both sam-
ples. The model was highly effective overall, but more effective in identifying
patients who died a NSCDthan it was in identifying patients who died a SCD.
Further investigation is needed todevelopa specific model to predict sudden
cardiac death.
m977156 TheNatureiHistoryof HeartFaiiureWithPreservedLeftVentricularSyetoiicFunction
E.F.Philbin, T. Erb, P.Jenkins. Maasachusetis General Hospital, Boston,
MA, USA, Bassefi Rasearch institute, Cooperstown, NE USA
To determine whether elderly heart failure (HF) patients with preserved LV
systolic function (diastolic HF) treated in the community have a prognosis
different than those with impaired LV contractility, we screened 1,402 con-
secutive patients admitted to 10 non-university hospitals and identified 801
whose LV function was assessed, Patients were followed prospectively for
8 months after discharge; death, hospital readmission and functional status
were tracked. Diastolic HF. present in 45Y0,was defined as clinical HF with
an LV ejection fraction (EF) ?40% or qualitatively normal LV contractility.
The rehospitalization rate was 43%; the cumulative death rate, 22%. The
groups differed in gender mix, age, serum sodium, hematocrit, prevalence of
cardiomsgaly and ventricular arrhythmia, and the use of certain medications.
Outcomeewere stratified by LVfunotion and adjustad for differences between
the groups. The risk-adjusted odds ratios for death and/or rehospitalization
associated with diastolic I-IFare shown:
Endooint Odds Ratio Confidence Interv D
All-causemortality 0.660 0.446-0.977
CHF death
0.036
0.680 0.403-1.146 0,147
Any rehospitalization 1.153 0.647-1.569 0.365
CHF rehospitalization 0.876 0.605-1.26S o.4e3
Death orrehospitalization 0.957 0.703-1.302 0.776
Mean hospital length of stay, rnpatient death rates, and pest-discharge
functional status measures were not different between the groups. Though
limited by small sample size, this study suggests that the risk-adjusted 6-
month death rate in the elderly with HF treated in the community is lower
among those with diastolic HF than those with systolic disease. These find-
ings support recommendations that LV function be measured in HF for ita
prognostic value.
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m977155 PredictingModeof DeathinAdvancedHeartFaiiure:Performanceofa ModeiDasignedto
PredictSurvivaiin PatientsReferredfor
TransplantEvacuation
K.D. Aaronson, D.M. Mancini. Division of C/rcu/atoryPhysiology, Columbia
Univerai~ New York,NY USA
We investigated whether a previously developed statistical model to predict
event-free survival (no death or urgent transplant [URGTXP]) in ambulatory
patients with CHF referred for TXP evaluation could be used to predict
sudden cardiac death (SCD).
The model was developed from 268 ambulatory patients with advanced
CHF at the Univ. of Penn. (HUP) (7/6&l/93) and validated on 199 patients
1977-1571 AiterationofPhyaicianBehaviorinthe Careof
CongestiveHeartFaiiurePatientsin the
CommunityHospiteiSettingUeingAmerican
Coiiegeof Cardiology/AmericanHeart
AssociationGuidelines
R.A. Rauh, N.J. Schwabauer, EL. Enger, J.F. Moran. Midwest Heart
Research Foundation, Lombard, IL, USA
Congestive heart failure (CHF) is the most frequent reason for admission
to the hospital. The management of these patients is frequently directed by
the family practitioner (FP) or medical internist (lM). Several studies have
confirmed that CHF patients cared for by FP or IM have longer lengths of
stay and more costly stays than CHF petients managed by cardiologists
(CD). Accordingly, we instituted an intensive education program directed
(EP) for the FP/lM based on American College of Cardiology/American Hearl
Association (ACC/AHA) guidelines for the management of CHF to alter this
pattern. The EP was not provided to CD to allow the group to sewe as a
control. Data on the mean length of stay (LOS) (s’= p .=0.05) and the mean
cost per case (o = p < 0.05) associated with these hospitalizations in patients
managed by IM, FP,snd CD prior to the provision of the EP (IM n = 105: FP
n = 373; CD n = 77) and following the EP (IM n = 64; FP n = 329; CD n = 71)
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are provided in the figures:
M F
IM FP CD IM FP CD
Conclusion: CHF LOS and cost in patients cared for by FP/lM can be
reduced by an intensive EP based on ACC/AHA guidelines.
m977158 Clinicai Determinants of Outcome in AdvancedHeart Faiiure: insighte from the PRAISE Triai
C.M. O’Connor, S.A. Anderson, R.B. Meese, J.K. Ghali, W.D. Old,
P.W.Willis, J.A. Bowers, D.A. Bramlet, A.B. Cropp, D.L. DeMets. Duke
University Medical Centec Durham, NC, USA
Understanding the relationship between baseline prognostic characteristics
and heart failure patients’ risk of death can help clinicians determine the
appropriate use of therapeutic strategies and facilitate the design of future
clinical trials.
In the PRAISE Trial of advanced heatt failure, 1,153 patients were ran-
domized to receive Amlcdipine vs placebo in addition to digitalis, diuretics
and ACE inhibitore. Baseline characteristics with respect to survival status
are shown below:
BsselineCharacteristics Alive Dead
Ags(yre.)(medianIQrangs) 65(57-72) 67(60-73)
IsohemicEtiology 59% 71”/0
NYHAClassIV 15% 26”/a
BloodPressure(SBP)mmHg 120(106-130) 110(100-124)
LVEF 21(17-25) 20 (15-25)
The independent predictor of outcome were: SBP (X2= 41), pulse pres-
sure (X2= 20), oerdiothoracic ratio (X2= 19), sodium level (X2= 18), low
weight (kg) (X2= 16), NYHA Class (X2= 15), LVEF (X2= 14), etiology (X2=
13), race (X2= 12), Ml hx (X2= 12), anti-arrhythmia drug hx (X2= 9), nitrate
use hx (X2= 7), aga (X2= 6), disease durstion (X2= 5), and hypertension hx
(X2,= 5).
In mnclusion, simple baseline clinical characteristics can discriminate
high risk from low risk heart failure patients and thus, may help clinicians
decide on the use of more aggressive therapiea and the design of future
clinical trials.
m977159 Contemporary Pattarns of Practice and Outcomesin Congestive Heart Faiiure Patiants Treated in a
Specialized Ciinic
K.K. Tee, F.A.McAliater, M. Taher, D.P.Humeri, R. Yim, L. Cheung, M. Kiaii,
T.J. Montague, P.W.Armstrong. University of A/Lrerta,.Edmorrton,Alberta,
Canada
Thia study reporle on the contemporav patterns of practice and outcomea in
586 consecutive patients referred to and followed up for an average of 51S
+ 490 days in a specialized CHF clinic attended by specialized medical and
nursing staff in a tertiary care hospital. Average age at initial presentation
was 68 + 14 years, 382 (6S%) were male, 380 (677.) had ikohemic heart
diseaae, 441 (76%) had systolic and the reet (22%) diastolic dysfunction. At
entry, 12% were in NYHA class 1,35% class H,36Y0class III and 15% class
IV. Medication used at last follow-up included ACE inhibitor (60%), loop
diuretics (80%), digoxin (60%), nitrates (49%), aapirin (60%), warfarfn (37%),
betablockers (26%), calcium channel blockers (18%), amiodarone (7%) and
magnesium supplement (9%).The most commonly prescribed ACE inhibitors
were enalapril (61Y0,mean dose 10.7 mg/day), Iisinopril (28%, 10.3 mg/day)
and captopril (9%, 62.1 m~day). Lifetable analysis showed one year survival
rates to be 90% for NYHA claas 1,86Y0for class H,777. class Ill and 56?4
class IV.Two year survival rates were 84%, 79Y0,66Y0and 34%, respectively.
Multivariate logistic regression analysis revealed that increased mortality riak
was associated with age >70 years (odds ratio [OR], 1.7, p = 0.01), NYHA
class IV (OR2.4, P= O.01),serum creatinine >130mmol/L (OR2.5, p= O.001)
and aystolic dysfunction (OR 2.1, p = 0.001). Betablockers were associated
with decreaaed mortality risk (OR 0.4, p = 0.002) while metolazone (OR 2.3,
P = 0.005) thiazides (OR 2.1, p = 0.05) and nitrates (OR 1.6, p = 0.03) were
associated with increased mortality risk. Compared to historical data, e.g.
the SOLVD Registv, these data suggest that treatment of patients with CHF
can be enhanced in a special CHF clinic with associated improved outcome.
1977-1601 patient SeieCtiOnforVentricuiar Ramodeiing
Surgery: Evoiving Criteria and Outcomes
R.C. Starling, J.B. Young, T.M. Buda, R.L. Vargo, N.G. Smedira,
P.M.McCarthy. The C/eve/and C/inic Foundation, C/eve/and, Ohio, USA
The Ieftventricular remodeling procedure (LVR) has been recently developed
as a treatment for patients (pts) with congestive heart failure (CHF). Some
centers have proposed that meet etiologies of heart disease will respond and
have reported perioperative mortality of ?25%. We believed that patients
with extensive coronary disease and prior infarction, irreversible myooyte
damage (e.g., adriamycin toxicity), primary myooyte diaorders and LV end
diastolic diameter (LVIDd) <7.0 cm would not be appropriate for LVR. Using
these criteria, 17 patients, 11 male, mean age 50.2 years, have undergone
LVR. Five patients were on chronic dobutamine pre-op, and 4 required
inotropic support during anesthesia induction. Operative mortality is O%,
and there have bean no deaths since the initial case was performed 105
days ago. The mean weight of LV mass resected was 78 + 31 grams (36-
136). Fourteen patients have been discharged. Two patients have required
post LVR support with an LV assist device; one had normal coronaries but
unrecognized remote infarction of the anteroseptal wall, and one sustained
an infarct perioperatively. One patient was found to have active myocerditia
after muscle resection and has required inotropic suppoti. The remaining
patients’ cardiac pathology has shown myocyte hypertrophy and interetiai
fibrosis (IF). Outcome cannot be predicted on the baais of extent of IF. We
believe that careful evaluation and selection criteria will define a patient
population likely to benefit from the LVR.
~977-1731prOgnOSiSandprOgreSSiOnOfEariyFaMiiiai
Diiated Cardiomyopathy: A 30 Month Prospective
Study
M.K. Baig, J.H. Goldman, AS. Coonar, A.L.P. Caforio, S. Sharma,
W.J. McKenna. St Georges Hospital, London, UK
Background: A subset of patients with dilated cardiomyo@hy (DCM) have
familial diseaae. We prospectively assessed relatives with abnormalities
suggestive of early diseaae.
Mathod:406asymptomatic relatives (mean age35 + 15,193 male) of 110
DCM patienta were assessed with non invasive cardiological assessment.
Results: 45 (20Yo)had LV enlargement (LVE ? 112% predicted), 13 (6%)
had depressed fractional shortening (FS -= 25%), 7 (3Yo)had established
DCM, and the remainder were normal. Abnormal WA ratio waa found in 40
(6S%) LVE and 60 (41%) normals. Relatives with LVE had lower E/A ratio,
lower % fs and larger LA dimensions than normale (1.29 + 0.72 vs 1.80
+ 0.71, p = 0.04), (33 + 6 VS35 + 6, p = 0.003), (35 + 5 VS33 + 5, p
= 0.001), reapactively. V02 max was abnormal in more LVES compared to
normals (4.9% vs 2.17., p < 0.05). LVE with abnormal VOZ % (<80Y0) had
a lower absolute VOZ max compared to normals (30 + 7.8 vs 42.5 + 9.1,
P = 0.01). dFS’s had larger LVDD% predicted (112 + 13 vs 102 + 7, p <
0.001), and lower RMS voltage.(30 * 8.9 mv vs 57.6 + 39.6 mv, p = 0.05)
than normals. Over 33 + 80.8 months follow-up, 12 LVE (27%), O relatives
with dFS, and 3 normal relatives (2%) developed DCM (p < 0.0001). Two
relatives with LVE died. No parameter at initial presentation waa predictive
of dieease progression.
Conclusions: 29% of asymptomatic relatives have echocerdiographic ab-
normalities, of whom 27% have progressed to develop overt DCM. The other
abnormalities aleo obsetved support the fact that these relatives have early
disease.
1977-1741 Does GendarHaveanimpacton Survival of
Patients With Heart Faiiure? Findings From the
SOLVD Regiatry
J.K. Ghali, D.H. Weiner, B. Greenberg, K. Adams, C. Benedict,
M. Quinones, for the SOLVD Registry Investigators. Louisiana State
University Shreveport, Louisiana, USA
The effect of gender on aurvival in patients with Heart failure (HF) and the
interaction with LV systolic function have not been well delineated. In order
to determine the effect of gender on long-term prognosis of patients with
Characteristics Males(n= 606) Females(n= 179)
NYHAI 217(36”/.) 55(31%) NS
II 290(460/.) 92(510/.)
Ill 69(15”/0) 29 (160/.)
PulmonaV congestion 139 (27”/.) 45 (29”/.) NS
LVEF > 450/a 156 (259A) 66 (360A) p <0.001
LVEF s 45”/0 461 (75”/0) 113 (62”A)
Heart Rate (bpm) 74.6 l 14.2 7S.1 + 14.2 p <0,005
CardioThoracicRatio 0,52 + 0.07 0.56 + 0.0S p <0.001
